Catalyst Wire Dossier Catalyst Wire Dossier

Ocaratuzumab

ocaratuzumab · Mentrik Biotech, LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Ocaratuzumab, covering 2014-03-03 to 2014-03-03. Get the full timeline:

Most recent: Clinical Trial Update: Phase I Study of Subcutaneous Ocaratuzumab in Patients With Previously Treated CD20+ B-Cell Malignancies [Phase 1]

See pricing